

[Budesonide](#)

Essential medicine status

Section:

[28. Ear, nose and throat medicines \[c\]](#)

ATC codes: [R01AD05](#)

EMLc

Indication

Allergic rhinitis ICD11 code: [CA07.0Z](#)

INN

Budesonide

Medicine type

Chemical agent

List type

Core

Formulations

Local > Nasal > Spray: 32 µg per actuation (EMLc) ; 64 µg per actuation (EMLc)

EML status history

First added in 2009 ([TRS 958](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Children (1 month - 12 years)

Therapeutic alternatives

Medicines within the same pharmacological class can be used

Therapeutic alternatives limitations for EMLc

Therapeutic alternatives to be reviewed

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Budesonide](#)

DrugBank

[Budesonide](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the strength of budesonide nasal spray be updated to reflect the available product strengths. The Committee also recommended the listing description be changed from 'per dose' to 'per actuation' as the administered dose may comprise more than one actuation (spray).